Diagnostic and Prognostic Evaluation of Vasorin During Septic Shock

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

144 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-19

Study Completion Date

2027-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Septic shock is the most severe form of infection. Currently, an early specific biomarker for septic shock is needed. Remember that shock situations are numerous, not only septic (eg hemorrhagic, cardiogenic...), and also accompanied by a severe pro-inflammatory state that it is sometimes difficult to distinguish from a septic state. Procalcitonin (PCT) is the most studied biomarker but still lacks sensitivity (77%) and specificity (79%). The investigators hypothesize that the Vasn could become this potential new biomarker and would allow a better diagnosis and thus the need or not to treat patients with antibiotics. The laboratory studies suggest a link between Vasn and septic shock. The goal of this project is to measure and compare plasma Vasn concentrations in 2 groups of patients = group 1: septic shock versus group 2: non-septic shock. Briefly, shock is defined as low blood pressure requiring vasopressor agents with confirmed infection (group 1) or without suspected infection such as patients admitted in intensive care unit post cardiac surgery with CBP (group 2). The investigators will also assess patient 28-day mortality to identify Vasn as a potential prognostic biomarker.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Prognostic Value of Immature Platelet Fraction

NCT07039227

Septic Shock

ACTIVE_NOT_RECRUITING

Interest of the Balance of Pro-coagulating and Profibrinolytis Activities of the Microparticles (MP) in the Prognosis of Septic Shock

NCT02062970

the Coagulolytic Balance the Mortality Rate the Performance Used to Evaluate the Principal Objective Are Technical Performances, Sensibility and Specificity of the Tests

UNKNOWN NA

Study of the Role of Interferon αon the Endothelial Dysfunction During Septic Shock

NCT04204694

Septic Shock

UNKNOWN

Citrulline and Arginase Activity in Severe Sepsis and Septic Shock

NCT03837730

Intensive Care Units Infection Biomarkers +2 more

COMPLETED

Proadrenomedullin and Copeptin in Patients With Septic Shock

NCT03104933

Septic Shock

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vasorin Septic Shock Shock Biomarker Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

in septic shock (infection)

Group Type EXPERIMENTAL

blood sample

Intervention Type BIOLOGICAL

blood sample in order to measure the concentrations of circulating Vasn

in shock without sepsis (without infection)

Group Type ACTIVE_COMPARATOR

blood sample

Intervention Type BIOLOGICAL

blood sample in order to measure the concentrations of circulating Vasn

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood sample

blood sample in order to measure the concentrations of circulating Vasn

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults over 18 years.
* Patients admitted for less than 24 hours in intensive care unit of the CHU Amiens Picardie.
* Group 1: patients with septic shock defined by sepsis with 2 mmol/l Lactates, requiring vasopressors to maintain mean blood pressure at 65 mmHg (despite adequate vascular filling) in the presence of fever (T°\>38.3) with a documented or suspected infection
* Group 2: patients with a shock defined by arterial hypotension requiring the use of vasopressors with 2 mmol/l Lactates but without suspected infection and apyrexie (T°\<38°). For example: vasoplegia post cardiac surgery with CBP or cardiogenic shock or hemorrhagic shock